540P_PR What are the patient expectations from palliative chemotherapy?

PURPOSE: The value of palliative chemotherapy in women with refractory and recurrent ovarian cancer is difficult to quantify, and little is known about patient expectations from these treatments. We evaluated in the current prospective study patient expectations, palliative outcomes of chemotherapy, and the inherent resource utilization in patients undergoing second- or third-line chemotherapy for recurrent or refractory advanced ovarian cancer. METHODS: The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire C30 (EORTC QLQ C30) and Functional Assessment of Cancer Therapy-Ovarian (FACT-O) questionnaires were used to assess palliative benefit and an in-house questionnaire was used to gauge patient expectations. The minimal clinically important difference (MCID) was calculated by asking women to make a global rating of change and correlating this to the EORTC QLQ C30. Resource use was recorded and costs were calculated. RESULTS: Twenty-seven patients were accrued. Objective response was documented on seven of 27. The median survival was 11 months. Sixty-five percent of women expected that chemotherapy would make them live longer and 42% that it would cure them. After two cycles, quality-of-life (QL) improvement was seen particularly in global function (11 of 21) and emotional function (13 of 21) with EORTC QLQ C-30. Improvement was sustained for a median of 2 and 3 months, respectively, in these categories. The MCID was calculated to be 0.39 on a seven-point scale for physical function and 0.13 for global function. The mean total cost per patient for the study period was Can $12,500. CONCLUSION: Patient expectations from these treatments are often unrealistic. Although objective responses are low, active palliation with chemotherapy is associated with substantive improvement in patients’ emotional function and global QL, with overall costs that seem relatively modest.

Download Full-text

What are the patient expectations from the palliative chemotherapy?

Annals of Oncology ◽

10.1093/annonc/mdw523.037 ◽

2016 ◽

Vol 27 ◽

pp. vii102

Author(s):

Nobumichi Takeuchi ◽

Sonomi Yoshida ◽

Takashi Rokuhara ◽

Zentaro Ohno ◽

Kumiko Koike ◽

...

Keyword(s):

Palliative Chemotherapy ◽

Patient Expectations

Download Full-text

540P_PR What are the patient expectations from palliative chemotherapy?

Annals of Oncology ◽

10.1093/annonc/mdw599.019 ◽

2016 ◽

Vol 27 (suppl_9) ◽

Author(s):

N. Takeuchi ◽

K. Koike ◽

K. Hotta ◽

S. Yoshida ◽

S. Yoshida

Keyword(s):

Palliative Chemotherapy ◽

Patient Expectations

Download Full-text

Patient Expectations Play a Role in Botox Effects

Skin & Allergy News ◽

10.1016/s0037-6337(06)71090-7 ◽

2006 ◽

Vol 37 (3) ◽

pp. 14

Author(s):

DAMIAN MCNAMARA

Keyword(s):

Patient Expectations

Download Full-text

Faculty Opinions recommendation of Patient expectations from implantable defibrillators to prevent death in heart failure.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.2577967.2232066 ◽

2010 ◽

Author(s):

Gad Cotter ◽

Olga Milo

Keyword(s):

Heart Failure ◽

Patient Expectations ◽

Implantable Defibrillators

Download Full-text

Chemical Anaplasia in Atypical Debut of Non-small Cell Lung Cancer with Inguinal and Obturator Lymph Node Metastases

Revista de Chimie ◽

10.37358/rc.18.10.6635 ◽

2018 ◽

Vol 69 (10) ◽

pp. 2833-2836

Author(s):

Laura Rebegea ◽

Aurel Nechita ◽

Cristina Serban ◽

Camelia Diaconu ◽

Luana Andreea Macovei ◽

...

Keyword(s):

Lung Cancer ◽

Lymph Node ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Lymph Node Metastases ◽

Palliative Chemotherapy ◽

Small Cell ◽

Lumbar Region ◽

Small Cell Lung ◽

Node Metastases

Non-small cell lung cancer (NSCLC) represents almost 80-85% of lung cancer cases. It is the most frequent malignancy after skin cancer. The therapeutic options for stage IV of disease consider histology, molecular characteristics, age, performance status, comorbidities, and not in the lust, patient�s option. This paper presents the case of a male patient, 73 years old, smoker, presented and treated in May 2016 in the Sf. Ap. Andrei Emergency Clinical Hospital Galati. The first sign of disease was inguinal and obturator right lymph node metastases whose histopathological test revealed metastases from malignant melanoma. Immunohistochemical tests (IHC) indicated undifferentiated carcinoma with lung as starting point, (Ck7 (+), TTF1 (+)). Thorax, abdominal and pelvic computed tomography (CT) imaging not evidenced space replacement processes in lung, but with mediastinal, right obturator and inguinal adenopathy. From personal pathological history we retain basocellular carcinoma in lumbar region, treated with surgery in 2009. It was initiated palliative chemotherapy and radiotherapy with remission of obturator and inguinal adenopathy, and at 9 months from diagnosis the Positron Emission Tomography (PET-CT) evidenced primary lung tumor situated in right superior lobe (RSL). At the present, patient is alive performing palliative chemotherapy. This case presented diagnostic and treatment issues, being a challenge for multidisciplinary team. We are mentioning the paucity of literature data regarding cases of primary tumors situated upper diaphragm which metastases in inguinal lymph nodes.

Download Full-text

Para-spermatic cord proximal-type epithelioid sarcoma

BMJ Case Reports ◽

10.1136/bcr-2019-232385 ◽

2021 ◽

Vol 14 (1) ◽

pp. e232385

Author(s):

Jessica Farnan ◽

Ellen Morrison ◽

Derek Barrry Hennessey

Keyword(s):

Spermatic Cord ◽

Median Overall Survival ◽

Palliative Chemotherapy ◽

Epithelioid Sarcoma ◽

Palliative Radiotherapy ◽

Surgical Excision ◽

Radical Excision ◽

First Line ◽

Left Groin ◽

Painless Mass

Proximal-type epithelioid sarcoma is an ultra-rare, high-grade soft tissue malignancy usually presenting as a deep-seated painless mass in the proximal extremities. Most patients are diagnosed as young adults, between 20 and 40 years of age. Perineal and genital masses do occur but are extremely rare and represent a challenging tumour to diagnose and treat. Early radical excision is recommended due to its aggressive behaviour and poor prognosis. Median overall survival from initial diagnosis is 30 months. We present the case of a 22-year-old man with a left groin proximal-type epithelioid sarcoma who is sadly deceased 12 months after initial presentation despite early surgical excision, completion of both first-line and palliative chemotherapy, and palliative radiotherapy.

Download Full-text

Undifferentiated Nasopharyngeal Carcinoma Presenting with Shoulder Mass

Case Reports in Oncological Medicine ◽

10.1155/2020/2586248 ◽

2020 ◽

Vol 2020 ◽

pp. 1-3

Author(s):

Cosphiadi Irawan ◽

Rahmat Cahyanur ◽

Reyhan Eddy Yunus

Keyword(s):

Palliative Chemotherapy ◽

Nasopharyngeal Cancer ◽

Bone Tumour ◽

Undifferentiated Carcinoma ◽

Neck Mass ◽

Definitive Treatment ◽

Unknown Primary ◽

Common Cancer ◽

Stage Ivb ◽

The Right

Nasopharyngeal cancer (NPC) is the most common cancer among head and neck cancer that usually presented with unilateral neck mass. Unusual symptoms of NPC can lead us to diagnosis misleading and delayed definitive treatment. We present a case of NPC with bone metastasis in the shoulder. A 33-year-old female presented with right shoulder mass caused by undifferentiated carcinoma of unknown primary, based on biopsy of shoulder mass. After four months, she was complaining painless neck swelling, headache, and hearing impairment in the left ear. Bone MRI showed malignant bone tumour in the right humerus. Neck CT scan showed mass in the nasopharyngeal and bilateral lymphadenopathy. Biopsy in nasopharyngeal revealed undifferentiated carcinoma of nasopharyngeal cancer (WHO-3 type A). The patient was diagnosed as NPC stage IVb and thus was treated with palliative chemotherapy. After three cycles of cisplatin docetaxel, patient condition improved.

Download Full-text